SkylineDx Expands Direct U.S. Commercial and Clinical Investment to Accelerate Access to Merlin™ CP-GEP

SkylineDx said it has expanded its direct U.S. commercial and clinical operations to accelerate access to Merlin™ CP-GEP. The company completed its shift from third-party commercialization to a fully integrated U.S. model, closing out third-party collaborations and establishing a dedicated sales, marketing and clinical organization. SkylineDx now has more than 25 professionals positioned across key U.S. markets, including roles working directly with clinicians in key territories. The move follows earlier milestones for Merlin CP-GEP, including publication of the prospective, blinded MERLIN_001 trial, inclusion in the NCCN Clinical Practice Guidelines in Oncology, and an FDA Breakthrough Device Designation. CEO Dharminder Chahal said the build-out moved from three sales representatives in early 2025 to the larger team.